Use of xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas
CA 2073633 C · Owner: Kittner, Barbara · Inventors: Gebert, Ulrich; Schubert, Hans-Peter; Kittner, Barbara
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The use of xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas (CCT), The use of xanthine derivatives of the formula I (see figure I), and of their physiologically tolerable salts in which R1, is oxoalkyl, hydroxyalkyl ar alkyl R2 is hydrogen or, alkyl and R3 is hydrogen alkyl, oxoalkyl or an alkyl, having up to 6 carbon atoms whose carbon chain is, interrupted by an oxygen atom for the production of, pharmaceuticals for the treatment of disorders which can occur after cranio-cerebral traumas is described.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 10, 1992 and granted September 23, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 10, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 10, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.